Quantcast
Last updated on April 18, 2014 at 17:16 EDT

Latest Asuragen Inc. Stories

2013-03-21 08:30:32

Fragile X syndrome is the most common inherited cause of intellectual disability and autism AUSTIN, Texas, March 21, 2013 /PRNewswire/ -- Asuragen Inc., a leading molecular diagnostics company, today announced results from a study demonstrating that a new molecular test called Xpansion Interpreter(®) can improve the determination of a woman's risk of having a child with fragile X syndrome, the most common inherited cause of intellectual disability and autism, compared to...

2008-09-09 06:00:39

Asuragen, Inc., announces that it has granted Focus Diagnostics, Inc., the infectious disease diagnostics company of Quest Diagnostics, non-exclusive worldwide rights to incorporate Armored RNA(R) technology into its in vitro molecular diagnostics products. Under the terms of the Agreement, Asuragen will develop and supply reagents for Focus Diagnostics in Asuragen's QSR-compliant manufacturing facility. Additional terms were not disclosed. Armored RNA(R) is a technology jointly invented...

2008-07-08 09:01:11

Affymetrix Inc. (NASDAQ:AFFX) and Asuragen Inc., a leading molecular biology diagnostic company and service provider, today announced an agreement to license, develop and manufacture in vitro transcription (IVT) reagent kits for clinical molecular diagnostic applications. The new IVT reagent kits developed and manufactured by Asuragen will enable Affymetrix to deliver a complete solution to its molecular diagnostic partners. The products will be optimally designed for clinical use and...